Delivering clinically proven treatments to patients with serious and underserved medical conditions worldwide.
Niihara International is a global pharmaceutical company focused on expanding access to proven therapies for patients with serious and underserved medical conditions. Guided by clinical science and decades of research, we work to reduce disease complications, improve quality of life, and expand treatment access worldwide.
Sickle cell disease affects more than 50 million people worldwide, with the greatest disease burden concentrated in Africa, India, and the Middle East. In many of these regions, patients lack consistent access to validated pharmaceutical treatments—not because solutions do not exist, but because supply chains, manufacturing capacity, and distribution models have failed to reach them.
Niihara International aims to change that reality.
Prioritizing regions with high disease prevalence and limited treatment availability, including sub-Saharan Africa, India, and parts of the Middle East.
Reducing reliance on multi-layered international distribution by developing streamlined, digitally enabled supply networks that lower cost and improve reliability.
Working with governments, hospitals, and public health organizations to ensure that therapies are delivered at scale, with consistent quality and predictable supply.
By reducing pain crises, hospitalizations, and disease complications, our therapies can help patients live more stable, productive lives while reducing the burden on healthcare infrastructure.
Through this approach, Niihara International seeks not only to deliver medicine—but to help build sustainable access to care.
